Roorkee scientists identify antiviral compounds in Ayurvedic cow urine distillate against Chikungunya virus
Roorkee, June 19
Researchers at the Indian Institute of Technology Roorkee have reported promising findings in the fight against Chikungunya, a mosquito-borne viral disease that continues to pose a significant public health challenge in tropical and subtropical regions.
The study identifies key bioactive compounds present in cow urine distillate (CUD) that demonstrate substantial antiviral activity against the Chikungunya virus (CHIKV), opening new avenues for the development of Ayurveda -inspired and affordable antiviral therapeutics.
The research, recently published in the prestigious journal ACS Agricultural Science & Technology, was led by Prof. Shailly Tomar and her team from the Department of Biosciences and Bioengineering, IIT Roorkee, in collaboration with researchers from leading Ayurveda and biomedical institutions across India. The study combined advanced virology, metabolomics, molecular docking, and biochemical analyses to identify compounds responsible for antiviral activity. Researchers found that treatment with cow urine distillate reduced Chikungunya viral levels by more than 90 per cent at safe concentrations, while an optimised combination of cow urine distillate, thymoquinone (derived from Nigella sativa), and piperine (from black pepper) achieved an impressive 99.85 per cent reduction in viral load under laboratory conditions, a release said. Further investigations identified benzoic acid, hippuric acid, and oleic acid as key constituents contributing to the antiviral activity. These compounds were shown to interfere with critical viral proteins involved in replication, highlighting their potential as candidates for future antiviral drug development. Speaking on the significance of the research, Prof. Kamal Kishore Pant, Director, IIT Roorkee, said, "Emerging and re-emerging viral diseases demand innovative, affordable, and scientifically validated solutions. This research exemplifies IIT Roorkee's commitment to advancing interdisciplinary science that bridges traditional knowledge systems with modern biotechnology to address pressing global health challenges." Highlighting the scientific importance of the findings, Prof. Shailly Tomar, Department of Biosciences and Bioengineering, IIT Roorkee, and corresponding author of the study, said, "Our research not only identifies specific bioactive molecules in Ayurvedic Gau mutra ark responsible for antiviral activity but also demonstrates the power of synergistic natural formulations. These findings provide a strong foundation for developing next-generation antiviral strategies against Chikungunya and potentially other related viral infections. Further pre-clinical and translational studies will be essential to evaluate their therapeutic applicability."
Chikungunya virus is transmitted primarily through Aedes mosquitoes and can cause severe fever, debilitating joint pain, and long-term health complications. Despite its growing global burden, there are currently limited antiviral treatment options available. The findings from IIT Roorkee contribute valuable scientific insights toward addressing this unmet medical need. The research was supported by the Ministry of AYUSH and involved extensive laboratory validation, computational screening, and antiviral testing. The study further underscores the importance of exploring natural bioactive compounds and integrative scientific approaches for developing future healthcare solutions, a release added.
— ANI
Reader Comments
Impressive numbers - 90% reduction is no joke. But we need to be careful about overhyping this. Let's wait for proper clinical trials before claiming it as a cure. Still, happy to see IIT Roorkee doing such innovative work! 👏
This is exactly what Atmanirbhar Bharat should look like in healthcare. We have centuries of Ayurveda wisdom, and now our top institutions are proving it works. The combination with black pepper and kalonji is pure genius - our grandmothers knew this all along! 🐄✨
As a researcher myself, I appreciate the rigorous methodology here - metabolomics, molecular docking, AND lab validation is a solid combo. But let's not forget Chikungunya is a neglected tropical disease; if this leads to an affordable treatment, it could benefit millions in rural India who can't afford expensive antivirals.
I've seen too many "Ayurvedic cure" claims go bust. But this time, it's published in ACS journal - that's a legit American Chemical Society publication! Still, 99.85% reduction in lab doesn't always translate to humans. Hope they move to animal trials soon. Skeptical but hopeful 🤞
We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.